Edgewise Therapeutics, Inc. (EWTX) Misses Q2 EPS by 6c

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) reported Q2 EPS of ($0.53), $0.06 worse than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Edgewise Therapeutics, Inc. (EWTX) click here.

You May Also Be Interested In

• Rapid7, Inc. (RPD) Tops Q2 EPS by 9c; offers guidance
• Mesa Laboratories (MLAB) Misses Q1 EPS by 139c
• North American Palladium (PAL) Misses Q2 EPS by 36c